Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies. To investigate the cellular origin(s) of this cancer, we determined the effect of PDAC-relevant gene mutations in distinct cell types of the adult pancreas. We show that a subpopulation of Pdx1-expressing cells is susceptible to oncogenic K-Ras-induced transformation without tissue injury, whereas insulin-expressing endocrine cells are completely refractory to transformation under these conditions. However, chronic pancreatic injury can alter their endocrine fate and allow them to serve as the cell of origin for exocrine neoplasia. These results suggest that one mechanism by which inflammation and/or tissue damage can promote neoplasia is by altering the fate of differentiated cells that are normally refractory to oncogenic stimulation.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the United States (Li et al., 2004) . Identification of the cell(s) of origin of PDAC and defining the biochemical and biological changes that accompany their transformation are essential for the development of early detection and treatment tools.
The pancreas is composed of four parenchymal cell types: acinar, ductal, centroacinar (exocrine), and islet (endocrine) cells. The acinar cells synthesize and secrete zymogens into the ductal lumen. The ducts carry the enzymes to the duodenum and generate bicarbonate. The centroacinar cells (CACs) have been suggested to be progenitor cells in the adult pancreas. The islets of Langerhans are composed of endocrine cell types, which secrete insulin and other proteins that regulate glucose homeostasis (Bardeesy and DePinho, 2002) . Rare cells expressing endocrine markers such as insulin can also be found associated with the acini and the ductal epithelium (Mills, 2007) .
PDAC arises from in situ precursor lesions termed pancreatic intraepithelial neoplasia (PanIN) (Hruban et al., 2001) . PanIN lesions include a spectrum of abnormal proliferative ductal structures (termed PanIN 1-3) that are recognized by transformation from a cuboidal to columnar epithelium, mucin production, and nuclear atypia.
Mutations that result in a constitutively active K-RAS are found in over 95% of PDACs and are believed to be an initiating event for this type of cancer (Jones et al., 2008; Rozenblum et al., 1997) . KRAS encodes a small GTPase that in its active GTPbound form promotes a wide range of cellular responses including proliferation, survival, migration, and metabolism (Shields et al., 2000) . The CDKN2A locus encodes the Ink4A and ARF tumor suppressor genes and is also frequently mutated in PDAC. INK4A inactivation mutations are present in virtually all
SIGNIFICANCE
The identification of the cell type(s) from which PDAC originates and is maintained is essential for the development of new methods for PDAC diagnosis and treatment. In this paper, we demonstrate that oncogenic K-Ras can transform Pdx1-expressing cells in the adult pancreas of the mouse in the absence of tissue injury. In contrast, insulin-expressing cells require injury in combination with K-Ras activation for transformation. Our study emphasizes the role of both genetic and nongenetic events in PDAC initiation and provides additional mouse models to aid in the development of new treatment and diagnostic strategies.
sporadic PDAC, suggesting that INK4A/ARF normally constrains the malignant potential of mutant K-RAS. Other frequent alterations include loss-of-function mutations of the SMAD4 and p53 tumor suppressor genes (Jaffee et al., 2002) . Moreover, developmental regulatory pathways, in particular the Notch, Sonic Hedgehog, and Wnt pathways, are often activated in PDACs (Berman et al., 2003; Miyamoto et al., 2003; Thayer et al., 2003; Wang et al., 2009) .
PDAC is commonly believed to arise from transformation of ductal cells, although experimental studies have suggested other differentiated cells or progenitor/stem cells as potential origin(s) for this type of cancer. For instance, mouse models expressing various oncogenes in acinar cells during development, such as the Elastase-Tgfa (Wagner et al., 1998) and ElastaseKras G12D (Grippo et al., 2003) transgenic strains and the knockin Mist1-Kras4B G12D animals (Tuveson et al., 2006) , have implicated acinar cells as being susceptible to transformation and giving rise to tumors containing ductal elements. Transplantation of mouse islet cell cultures expressing the polyoma virus middle T oncogene into histocompatible mice resulted in the induction of pancreatic cancer with ductal histology (Yoshida and Hanahan, 1994) , suggesting a potential endocrine origin for PDAC. A role of CACs has been proposed based on studies of mice that harbor a pancreas-specific deletion of the PTEN gene; these animals exhibit a proliferative expansion of CACs that can progress to carcinoma (Stanger et al., 2005) . Nestin + exocrine progenitor cells have been shown to be highly responsive to K-Ras oncogenic activation and were suggested to represent a progenitor origin for PDAC (Carriere et al., 2007) . The close developmental relationships of the different pancreatic cell types and the capacity of endodermal lineages to transdifferentiate (Slack, 1995) add complexity to the PDAC cell-oforigin question. PanIN lesions can express markers of gastric and foregut differentiation (Prasad et al., 2005) , suggesting that some degree of transdifferentiation occurs routinely during PDAC progression. This developmental plasticity is evident in some human PDACs that show focal expression of nonductal lineage markers, including endocrine and exocrine factors. More recently, Habbe et al. (2008) and De La O et al. (2008) have shown that activation of oncogenic K-Ras in acinar cells of the adult mouse leads to efficient mPanIN formation. These groups have also demonstrated in vivo acinar-to-ductal transdifferentiation by lineage tracing studies in these models (De La O et al., 2008; Habbe et al., 2008) . Given this plasticity, it is possible that there is no exclusive cell of origin for PDAC and that specific genetic alteration(s) define the resulting malignant phenotype regardless of the cell in which they occur. Moreover, the physiological context, including tissue damage and inflammation, may alter a given cell's susceptibility to transformation. For example, Guerra et al. (2007) have reported that K-Ras activation in acinar cells (using the K-Ras +/LSLG12Vgeo ;Elas-tTA/tetO-Cre system) resulted in adult onset malignancy only following treatment with caerulein, which causes tissue injury and inflammation (Guerra et al., 2007) . In this study, we investigate whether PDAC arises from an exclusive cell of origin and whether a combination of genetic and nongenetic events can collaborate to induce neoplasia in a range of cell types. We describe the use of genetic manipulation of the mouse to systematically determine the effects of oncogenic K-Ras in distinct subsets of pancreatic cells of the adult mouse in a context-dependent manner.
RESULTS
Temporally Restricted Activation of Oncogenic K-Ras in Distinct Cell Populations of the Adult Pancreas Activation of oncogenic K-Ras in the common pancreatic embryonic progenitor in the Pdx1Cre;LSL-Kras G12D model results in mPanIN formation and spontaneous progression to PDAC (Aguirre et al., 2003; Hingorani et al., 2003) . Because human PDAC is an adult-onset malignancy, we sought to engineer PDAC mouse models in which oncogenic K-Ras (Kras G12D ) is activated in the adult animal. We crossed the LSL-Kras G12D strain to different cell-specific CreER lines and compared the phenotypic effect of Kras G12D activation on these distinct cell populations in the adult pancreas ( Figure 1A ). The CreER lines used were: (1) the Pdx1CreER TM transgenic strain (Gu et al., 2002) , which marks the earliest pancreatic progenitor cell during development as well as adult endocrine b cells, some ductal, acinar cells, and possibly adult progenitor/stem cells (Koizumi et al., 2003; Stoffers et al., 1999; Swift et al., 1998; Wu et al., 1997) ; (2) the RipCreER TM transgenic strain (Dor et al., 2004) , which is selective for insulin + cells; and (3) the acinar procarboxypeptidase A1 CreER T2 (proCPA1CreER T2 ) knockin strain (Zhou et al., 2007) . The recombination specificity and efficiency of the different CreER strains was determined by crossing them to the LSL-LacZ reporter mouse and analyzing the X-gal-stained pancreata of their Tamoxifen (TM)-treated compound progeny  (Figures 1B-1E and Table S1 available online). As shown in Figure 1B , in the Pdx1CreER TM transgenic strain, recombination was achieved in a mosaic fashion in the islets, acinar, and ductal cells. The proCPA1CreER T2 strain exhibited recombination mainly in acinar cells and possibly CACs; however, recombination was evident also in a subset of ductal and islet cells. Recombination in this strain was variable, with half of the treated mice showing no evidence of recombination and the other half ranging from 0% to 49% in acinar cells ( Figure 1C , Table S1 , and data not shown). With TM administration, the RipCreER TM transgenic strain was very specific and efficient in causing recombination in both insulin-producing b cells located in the islets of Langerhans and in single insulin + cells found scattered throughout the pancreas parenchyma, as shown by X-gal and coimmunofluorescent (CoIF) staining ( Figures 1D and 1E , respectively, and Table S1 ).
Expression of Kras G12D in different cell types of the adult pancreas was achieved by systemic TM administration in mice at 14-56 days of age. Because newly transformed cells would be expected to resemble their cell of origin both genetically and morphologically, we sought to define the earliest time point when transformed cells could be detected after TM administration. Therefore, mice were sacrificed at different times following the last dose, ranging from 4 to 240 days. Figure 2 and Table S2 ). Low-grade mPanIN 1A lesions were the most prevalent and were observed to a comparable extent across the three main age groups, whereas mPanIN 1B were less frequent in the 56-day-old group. Although mPanIN lesions were predominantly grade 1, grade 2 lesions were also identified, mostly at 120 days after TM administration and only in the 14-and 27-day-old treated mice (Table S2 and Figure 2E ). These results suggest that the Pdx1 + target cell for transformation is either less susceptible or less abundant in 56-day-old mice. mPanIN 3 was found only in one mouse that was analyzed 188 days after TM administration, and it was also the only mouse that developed PDAC. This result is consistent with observations in humans that it is unusual to find PanIN 3 in pancreata lacking invasive carcinoma (Mills, 2007) .
TM-treated 14-or 27-day-old mice exhibited additional phenotypes (n = 23). One of the most notable was the appearance of acinar cells and ductal structures ''embedded'' in the islets of Langerhans as soon as 10 days after TM treatment ( Figures 3A and 3B , respectively). The ductal structures grew over time ( Figure 3C ) and remained proliferative (data not shown). These lesions became elongated and produced mucin, reminiscent of mPanINs ( Figure 3D ). In contrast, some mPanIN in the exocrine compartment harbored cells that positively stained for endocrine markers such as glucagon, insulin, somatostatin, and PYY (Figures S1A and S1B and data not shown). Other histologic findings at 120 days after TM treatment included robust atrophy of the pancreas with a hypoplastic exocrine compartment, large cystically dilated areas, and strong stromal reaction G12D strain was crossed to the insulin + cell specific RipCreER TM strain (Dor et al., 2004) ; to the acinar proCPA1CreER T2 strain (Zhou et al., 2007);  and to the putative stem/progenitor cell specific Pdx1CreER TM strain (Gu et al., 2002) . (Figures S1C and S1D). Importantly, no lesions arose in vehicletreated mice (n = 15) (Table S2 ). These results exclude the possibility of leaky Cre recombinase activity and TM-independent K-Ras activation during development and/or adulthood. In addition, we observed no evidence of chronic pancreatitis in treated mice. Since TM is dissolved in corn oil, which by itself causes a mild form of peritonitis ( Figure S1E ), we treated Pdx1CreER TM ;LSL-Kras G12D mice with TM dissolved in carboxymethyl cellulose (CMC) by oral gavage. Dissolving TM in corn oil or CMC did not affect the specificity and efficiency of Cre-induced recombination as confirmed by X-gal staining in mice harboring a LacZ reporter (data not shown). As shown in Figure S1F , pancreata of mice treated with TM dissolved in CMC were free of peritonitis yet still developed grade 1 mPanINs (n = 5). This result precludes the possibility that the corn oilinduced peritonitis was essential for formation of mPanINs and ductal metaplasia in the Pdx1CreER
Activation of Kras G12D in combination with mutations of Ink4A/ Arf (Aguirre et al., 2003) or Trp53 (Jonkers et al., 2001) in Pdx1 + cells in the adult mouse resulted in formation of moderately to poorly differentiated PDAC in 10/13 mice tested ( Figure 4 and Table S2 ). Many of the tumors contained undifferentiated areas with sarcomatoid or anaplastic features, and extension beyond the pancreas was common. We observed direct invasion into the stomach and small intestine as well as metastasis to mediastinal lymph nodes, diaphragm, and peritoneal adipose tissue ( Figure 4 and data not shown). We also identified a full range of mPanIN lesions in these mice, including grade 3 (Table S2 mice with TM resulted in low grade mPanIN-1A formation in only 2/20 mice (Table S3 and Figure S2A ). All mice were tested and confirmed for LSL-Kras G12D recombination by PCR analysis of DNA extracted from tissue sections (Table S3) ElaCreERT strains (De La O et al., 2008; Habbe et al., 2008) . The phenotypic diversity observed between these models is discussed below (see also flox/flox mouse (n = 5) developed a moderately to poorly differentiated PDAC 81 days after TM injection at 53 days of age. The tumor contained undifferentiated areas, was locally invasive, and metastasized to the liver and diaphragm (Table S3 and Figure S2B ). As described earlier, all mice in this study were analyzed for DNA recombination by PCR (Table S3) . We conclude that highly aggressive PDAC can be initiated in proCPA1 + cells in adult mice without chronic pancreatitis, albeit with low penetrance in this system.
In a previous study, Guerra et al. (2007) reported that selective expression of an endogenous K-Ras (G12V) oncogene in adult cells of the acinar/centroacinar lineage using the K-Ras
; Elas-tTA/tetO-Cre mouse model resulted in no phenotype unless the mice were pretreated with caerulein (Guerra et al., 2007) . Caerulein induces chronic pancreatitis that results in regeneration of normal tissue and formation of metaplastic lesions of a ductal phenotype in the exocrine compartment (Strobel et al., 2007) . The authors concluded that chronic pancreatitis can be a cofactor in the induction of PDAC by the K-Ras (G12V) oncogene in adult mice (Guerra et al., 2007) . Because the proCPA1CreER T2 ; LSL-Kras G12D mice described above were largely refractory to Kras G12D -induced transformation, we set out to test whether chronic pancreatitis could facilitate PDAC formation in these mice.
We treated 34-to 60-day-old mice (n = 9) with caerulein for a total of 44-193 days. One month after caerulein treatment initiation, the mice were treated with TM to activate Cre. In addition to caeruleininduced inflammation and ductal metaplasia, 3/9 proCPA1 CreER T2 ;LSL-Kras G12D and proCPA1CreER T2 ;LSL-Kras G12D ; LSL-LacZ mice developed grade 1 mPanINs ( Figure 5A and Table S4 ). We confirmed LSL-Kras G12D recombination by PCR analysis of DNA extracted from laser-captured microdissected (LCM) lesions ( Figure 5C and ;LSL-LacZ mice were treated with caerulein for a total of 84 and 89 days. One month after caerulein treatment initiation, the mice were treated with TM to activate Cre. Interestingly, grade 1 mPanINs were detected in one of these mice ( Figure 5B and Table S4 ). We confirmed LSL-Kras G12D recombination in the pancreas of the mouse that did not show mPanIN formation as well as in mPanINs derived from the second mouse by PCR analysis of DNA extracted from tissue section and of DNA extracted from LCM lesions, respectively ( Figure 5C and Table S4 ). Hence, the mPanINs observed arose from cells in which the transgenic rat insulin promoter was active. Importantly, all three RipCreER TM ; ;p53 flox/flox ;LSL-LacZ mice developed poorly and undifferentiated PDAC (n = 2 and n = 1, respectively) when treated first with caerulein and then with TM ( Figure S3D and Cancer Cell K-Ras-Induced Tumorigenesis in Adult Pancreas pulsed the triple compound progeny of these mice with TM 7-14 days prior to caerulein treatment initiation (n = 6) ( Table S4) . In this way, differentiated insulin + cells and their progeny would be marked by the LacZ expression and their fate could be identified after caerulein treatment by X-gal staining ( Figure 5D ). Strikingly, LacZ + mPanINs were found in 4/6 pancreata of these mice ( Figure 6A and Table S4 ). In the remaining two mice mPanINs were not observed, which might be explained by the small pancreatic area analyzed (less than 2 mm 2 ; Table S6 ). In addi- (Table S1 ), Cre activity was more promiscuous under chronic pancreatitis conditions. This result raised the possibility that the mPanIN lesions observed in the experiment described above arose in non-insulin-expressing cells following inappropriate Cre activation during the caerulein treatment. To address this possibility directly, we treated RipCreER TM ;LSL-LacZ mice (n = 5) with TM for 5-7 days, treated them with caerulein for 65 days, and subsequently analyzed them for coexpression of LacZ and insulin by CoIF (Table S5) Figures 6B and 6C ). Although the mechanism through which mature insulin-producing cells undergo this fate change is unclear, it is notable that these mPanINs harbored Pdx1
+ cells and cells that positively stain for the Notch intracellular domain ( Figure 6E and data not shown mice and also resembled human undifferentiated pancreatic carcinoma (Hoorens et al., 1998) . Tumors in these mice were negative for insulin as well as the neuroendocrine marker synaptophysin by IHC ( Figures 7C and 7D) . Furthermore, no preneoplastic lesions were observed in the islets of these mice (data not shown). In conclusion, our results provide evidence that in combination with pancreatic injury, Kras
G12D
-expressing insulin + cells of the endocrine lineage, which are refractory to transformation under normal conditions, can also serve as a cell of origin of PDAC, a malignancy with an exocrine phenotype.
DISCUSSION
We have studied the susceptibility of adult pancreatic cells to transformation by Kras
G12D
. We show that Pdx1 + cells can efficiently give rise to mPanIN and ductal metaplasia and, in combination with p53 or Ink4A/Arf deletion, can develop into PDAC. In CreERT2/+ (Habbe et al., 2008) ; ElaCreERT (De La O et al., 2008) ; and the proCPA1CreER T2 studied here. Different phenotypes, ranging from no lesion to high-grade mPanIN-3 formation, were observed in these strains (Table S7 ). The phenotypic diversity might be explained by several factors, including:
(1) the K-Ras +/LSLG12Vgeo strain lacks the 3 0 UTR element, which contains several regulatory sequences, including binding sites for the let-7 miRNA family that regulates both N-Ras and K-Ras (Johnson et al., 2005) , and has been suggested to function in tumor suppression (Lee and Dutta, 2007; Mayr et al., 2007; Takamizawa et al., 2004; Yu et al., 2007) . Thus, the more abundant lesion formation in the 10-day-old K-Ras +/LSLG12Vgeo ;
Elas-tTA/tetO-Cre mice compared to the proCPA1CreER T2 ;
LSL-Kras G12D may result from more tightly controlled translational repression of Kras G12D versus K-Ras (G12V) . (2) The models utilize distinct K-ras activating mutations (G12V versus G12D), which might have an effect on the oncogenic potency of K-Ras (Bardeesy and Sharpless, 2006; Collado et al., 2005; Seeburg et al., 1984) . (3) Recombination efficiency differences between the different strains may exist, either because of differences between Cre-driving promoters, per se, mouse background, or different TM and doxycycline administration protocols. (4) The different mouse models may reflect a previously uncharacterized heterogeneity of acinar cells with respect to function and/or susceptibility to transformation. Nevertheless, the collective observations provide evidence that there are acinar cells in the adult pancreas sensitive to oncogenic K-Ras activation that can progress to at least mPanIN in the absence of overt tissue injury and that highly aggressive PDAC can be initiated from proCPA1 + cells, albeit with low penetrance. When injury was induced before recombination, the Strobel et al. (2007) in RipCreER TM ;Z/AP mice. Interestingly, oncogenic K-Ras activation is rarely observed in human endocrine tumors (Jonkers et al., 2007) . This may in part be explained by reprogramming of endocrine cells to an exocrine fate upon injury and K-Ras activation.
The (Hingorani et al., 2003) . This may reflect a developmental compensation mechanism or result from mouse background differences.
Caerulein might promote Kras
-induced transformation by several mechanisms. It is possible that a rare population of proCPA1-and/or insulin-expressing progenitor cells that are normally susceptible to Kras G12D oncogenic effect needs to be amplified by tissue injury for the appearance of the phenotype. Another possibility is that injury-induced regeneration or the secretion of inflammatory cytokines leads to the proliferation of stem cell/facultative stem cells that are most probably Pdx1 + .
Upon the initiation of differentiation of such cells, a subset might transiently express either proCPA1CreER T2 or RipCreER TM and, thus, activate Kras G12D upon TM administration. However, our results provide evidence that proCPA1-and insulin-expressing cells can form mPanINs, favoring the hypothesis that inflammation and tissue injury facilitate PDAC development by promoting reprogramming of differentiated cells rather than by stem cell mobilization. The mechanism through which such a reprogramming event might occur requires further investigation. However, our study and those of others suggest a role for the Notch signaling pathway in this process. Caerulein-derived acinar-ductal metaplasia is associated with Notch pathway upregulation (Gomez et al., 2004; Jensen et al., 2005; Siveke et al., 2008) . We also found Notch to be activated in mPanINs derived from caerulein/TM RipCreER TM ;LSL-Kras G12D mice. Reactivation of the Notch signaling pathway, which is important for cell-fate decisions and maintenance of undifferentiated stem/progenitor cells during embryogenesis (Artavanis- Tsakonas et al., 1999) , may be a mechanism by which differentiated cells can revert to a stem/ progenitor fate or to convert to a cell type that is sensitive to Kras G12D activity. It has been recently shown that Notch and K-Ras reprogram acinar cells to mPanINs (De La O et al., 2008 ). The precise mechanism of, and requirement for, interaction between chronic pancreatitis, Notch, and K-Ras activation for mPanIN formation from different pancreatic cells still needs to be determined. These data add to the increasing body of evidence pointing to a remarkable plasticity of pancreatic adult differentiated cells (De La O et al., 2008; Habbe et al., 2008; Shen et al., 2000; Zhou et al., 2008) (Xu et al., 2008) . It is possible that this cell type is activated only in certain settings such as injury and neoplasia and may be particularly susceptible to Kras
-induced proliferation and differentiation. It might also be the source of the ductal structures located in the islets, if it resides both in the ductal lining as well as the islets or if it migrates to the islets under certain conditions. Alternatively, these structures may arise from a differentiated cell, such as the carbonic anhydrase II + cell that gives rise to endocrine and exocrine cells after birth and injury (Inada et al., 2008) , upon Kras G12D activation.
Our study reveals the involvement of different cell types in PDAC initiation and provides a series of models to explore the biology and treatment of PDAC. With the advances in the ability to reprogram adult pancreatic cells in a controlled manner (Zhou et al., 2008) , we expect that a better understanding of the reprogramming and transforming events attributed to Kras G12D activation in combination with chronic inflammation will lead to the development of new therapeutic modalities to prevent PanIN formation or to repair the diseased/damaged tissue. (Dor et al., 2004) , Trp53 flox (Jonkers et al., 2001) , and Ink4A/Arf flox (Aguirre et al., 2003) . Primers used for genotyping by PCR are listed in Table S8 and details of reactions are available upon request. Cre strains were crossed to R26 LSL LacZ mice (Jackson Laboratories) to determine Cre expression patterns.
Histopathology, Immunohistochemistry, and Immunofluorescence Histopathologic analysis of pancreata was carried out by two pathologists (G.C.C. and E.L.S.). mPanIN lesions and PDAC were graded according to consensus criteria for mouse models of pancreatic cancer (Hruban et al., 2006) . We carried out IHC and IF analyses according to manufacturers' recom mendations, typically with a modified citric acid unmasking protocol followed by standard detection with 3,3 diaminobenzidine with a kit from Vector Labo ratories. In some cases, secondary antibodies were conjugated to AlexaFluor 594 (Invitrogen) and nuclei were counterstained with 4,6 diamidino 2 phenyl indole. We used the following primary antibodies: insulin (Zymed), glucagon (Abcam), PYY (RDI), Pdx1 (gift of C.V. Wright), CPA1 (Chemicon), and b galac tosidase (AbD Serotec). IF staining was performed as described previously (Jackson et al., 2001) . Triple color microscopy and imaging were performed with a Nikon Eclipse E600 and a Spot cooled CCD camera and software. Images were processed with Adobe Photoshop.
b-Galactosidase Histochemistry Pancreata were dissected and fixed in 4% PFA, incubated in 0.5 M Sucrose, and frozen in OCT. b galactosidase activity was assayed as describe previ ously (Paratore et al., 2002) .
Tamoxifen Treatment
Mice were treated with TM (Sigma) by intraperitoneal injections (i.p.) of 9 mg/ 40 g body weight in corn oil, one every other day for a total of three injections. For oral delivery, TM was dissolved in a 0.5% CMC, 0.4% Tween 80, and 0.9% NaCl solution.
Caerulein Treatment
Mice were i.p. injected with 0.1 ml of a 50 mg/ml caerulein (Sigma) in saline solution five times per week.
Pancreata Size Measurement
Pancreata areas were determined with Bioquant Image Analysis software in manual measurement mode. 
Molecular Analysis

